Biogen (BIIB) Cash from Financing Activities (2016 - 2025)
Historic Cash from Financing Activities for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$137.0 million.
- Biogen's Cash from Financing Activities fell 183417.72% to -$137.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$301.9 million, marking a year-over-year increase of 5583.03%. This contributed to the annual value of -$301.9 million for FY2025, which is 5583.03% up from last year.
- As of Q4 2025, Biogen's Cash from Financing Activities stood at -$137.0 million, which was down 183417.72% from -$130.2 million recorded in Q3 2025.
- Over the past 5 years, Biogen's Cash from Financing Activities peaked at $848.6 million during Q3 2023, and registered a low of -$1.3 billion during Q3 2022.
- Its 5-year average for Cash from Financing Activities is -$233.5 million, with a median of -$86.8 million in 2023.
- Examining YoY changes over the last 5 years, Biogen's Cash from Financing Activities showed a top increase of 16778.5% in 2023 and a maximum decrease of 863108.11% in 2023.
- Quarter analysis of 5 years shows Biogen's Cash from Financing Activities stood at $9.8 million in 2021, then plummeted by 175.51% to -$7.4 million in 2022, then crashed by 8631.08% to -$646.1 million in 2023, then surged by 101.22% to $7.9 million in 2024, then plummeted by 1834.18% to -$137.0 million in 2025.
- Its Cash from Financing Activities stands at -$137.0 million for Q4 2025, versus -$130.2 million for Q3 2025 and -$11.7 million for Q2 2025.